Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High- Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Conditions:   Ovarian Neoplasm;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms Interventions:   Drug: Nab paclitaxel 80 mg/m^2;   Drug: Relacorilant 150 mg once daily (QD);   Drug: Liposomal doxorubicin 40 mg/m^2;   Drug: Paclitaxel 80 mg/m^2;   Drug: Topotecan 4 mg/m^2;   Drug: Topotecan 1.25 mg/m2;   Drug: Nab-paclitaxel 100 mg/m2 IV Sponsor:   Corcept Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials